Mangoceuticals, Inc. (MGRX)

NASDAQ: MGRX · Real-Time Price · USD

2.470

+0.140 (6.01%)

At close: Nov 20, 2024, 4:00 PM

2.410

-0.060 (-2.43%)

Pre-market: Nov 21, 2024, 5:28 AM EST

Mangoceuticals Employees

Mangoceuticals had 3 employees as of December 31, 2023. The number of employees increased by 1 or 50.00% compared to the previous year.

Employees

3

Change (1Y)

1

Growth (1Y)

50.00%

Revenue / Employee

$251,667

Profits / Employee

-$3,108,613

Market Cap

5.85M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	3	1	50.00%
Dec 31, 2022	2	0	-
Dec 31, 2021	2	-	-

Related Stocks

Company Name	Employees
Mainz Biomed	71
Biora Therapeutics	58
Sharps Technology	57
Intelligent Bio Solutions	50
Ainos	46
Viracta Therapeutics	40
TransCode Therapeutics	10
Alzamend Neuro	7

Employee Rankings

MGRX News

4 weeks ago - MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly - GlobeNewsWire
4 weeks ago - Mangoceuticals, Inc. Announces Participation at the Centurion One Capital 2nd Annual Bahamas Summit 2024 - Newsfile Corp
5 weeks ago - Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter - Benzinga
5 weeks ago - MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLAN - GlobeNewsWire
7 weeks ago - MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions - GlobeNewsWire
7 weeks ago - MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment - GlobeNewsWire
3 months ago - MangoRx Reports 1,685% Increase in Shareholders' Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024 - GlobeNewsWire
3 months ago - MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide - GlobeNewsWire